Core Viewpoint - The WPP class action lawsuit alleges that WPP plc and its executives misled investors regarding the company's revenue outlook and growth potential during the specified Class Period, leading to significant financial losses for shareholders [3][4]. Group 1: Lawsuit Details - The class action lawsuit is titled Marty v. WPP plc and covers the period from February 27, 2025, to July 8, 2025 [1]. - The lawsuit claims that WPP created a false impression of its financial health and growth prospects while downplaying risks associated with seasonality and macroeconomic factors [3]. - On July 9, 2025, WPP reported a deterioration in performance, attributing it to macroeconomic uncertainties and weaker new business than expected, which led to an over 18% drop in stock price [4]. Group 2: Company Background - WPP positions itself as a creative transformation company offering services in communications, experience, commerce, and technology [2]. - The company has faced challenges in its media arm, which has reportedly lost market share to competitors [3]. Group 3: Legal Process - Investors who purchased WPP common stock during the Class Period can seek to be appointed as lead plaintiff in the lawsuit, representing the interests of the class [5]. - The lead plaintiff has the authority to select a law firm for the litigation, but participation as lead plaintiff is not necessary for potential recovery [5]. Group 4: Law Firm Profile - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6]. - The firm has a strong track record, being ranked 1 in securities class action services for four out of the last five years [6].

NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Semler Scientific, Inc. ("Semler Scientific, Inc." or the "Company") (NASDAQ: SMLR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Semler Scientific, Inc. investors who were adversely affected by alleged securities fraud between March 10, 2021 and April 15, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.co ...

Core Viewpoint - A class action securities lawsuit has been filed against LifeMD, Inc. for alleged securities fraud affecting investors between May 7, 2025, and August 5, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that defendants materially overstated LifeMD's competitive position [2]. - It is alleged that defendants were reckless in raising LifeMD's 2025 guidance without properly accounting for rising customer acquisition costs in the RexMD segment and related to obesity treatment drugs [2]. - As a result, the statements made by defendants regarding LifeMD's business, operations, and prospects were materially false and misleading [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until October 25, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

Core Viewpoint - A class action securities lawsuit has been filed against Fortinet, Inc. for alleged securities fraud affecting investors between November 8, 2024, and August 6, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Fortinet's management made false statements regarding the refresh cycle of their products, suggesting it would be more profitable than it actually was, as it involved old products that represented only a small portion of the company's business [2]. - It is alleged that Fortinet misrepresented the number of FortiGate firewalls eligible for upgrades and that the company had pushed through approximately half of the refresh in just a few months, contrary to claims of a two-year momentum [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 21, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A class action securities lawsuit has been filed against Fluor Corporation, alleging securities fraud that negatively impacted investors between February 18, 2025, and July 31, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Fluor Corporation made false statements regarding the rising costs of its infrastructure projects, including Gordie Howe, I-635/LBJ, and I-35, due to subcontractor design errors, price increases, and scheduling delays [2]. - It is alleged that these issues, along with reduced capital spending from customers and economic uncertainty, significantly harmed the Company's business and financial results [2]. - The complaint asserts that Fluor's financial guidance for FY 2025 was unreliable, overstating the effectiveness of its risk mitigation strategy and understating the impact of economic uncertainty [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until November 14, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, highlighting its expertise in complex securities litigation [4].

Core Viewpoint - A class action securities lawsuit has been filed against KBR, Inc. alleging securities fraud that affected investors between May 6, 2025, and June 19, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that KBR, Inc. made false statements regarding its partnership with HomeSafe, despite knowing that the U.S. Department of Defense had concerns about HomeSafe's ability to fulfill a global household goods contract [2]. - It is alleged that the defendants' statements about KBR's business operations and prospects were materially false and misleading, lacking a reasonable basis during the relevant time [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified period have until November 18, 2025, to request to be appointed as lead plaintiff in the case [3]. - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cytokinetics investors who were adversely affected by alleged securities fraud between December 27, 2023 and May 6, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/cytokinet ...

Core Viewpoint - V.F. Corporation is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between October 30, 2023, and May 20, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that V.F. Corporation made materially false and misleading statements regarding its turnaround plans, particularly concerning the Vans brand, which required significant reset actions to return to growth [2]. - Following the release of V.F. Corporation's fiscal 2025 results on May 21, 2025, it was revealed that Vans' revenue growth trajectory had significantly declined, with losses increasing from 8% to 20% in the fourth quarter [2]. - The company's results were attributed to deliberate actions taken to eliminate unprofitable businesses, which were previously unannounced, and even without these actions, Vans would have shown a high single-digit revenue decline [2]. Group 2: Stock Price Impact - On May 21, 2025, following the disclosure of the negative financial results, V.F. Corporation's stock price dropped from $14.43 to $12.15 per share, marking a decline of approximately 15.8% in one day [2]. Group 3: Next Steps for Investors - Investors who suffered losses during the relevant period have until November 12, 2025, to request to be appointed as lead plaintiff in the lawsuit, although participation does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 4: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].

Core Viewpoint - Savara Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between March 4, 2024, and May 23, 2025 [1] Group 1: Allegations and Impact - The lawsuit claims that Savara Inc. made false statements regarding the MOLBREEVI Biologics License Application (BLA) for the treatment of pulmonary alveolar proteinosis, indicating insufficient information about its chemistry, manufacturing, and controls [2] - It is alleged that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [2] - The public statements made by the defendants were materially false and misleading throughout the relevant period, impacting investor decisions [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until November 7, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, ensuring no financial burden to participate [3] Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders and being recognized as one of the top firms in the United States for seven consecutive years [4]

Core Viewpoint - A class action has been initiated against Cepton, Inc. for securities fraud during the specified class period from July 29, 2024, to January 6, 2025, with a deadline for lead plaintiff motion filings set for December 8, 2025 [1]. Group 1 - The Portnoy Law Firm is advising investors who purchased Cepton securities during the class period to take legal action [1][2]. - Investors can contact attorney Lesley F. Portnoy for a complimentary case evaluation and to discuss their legal rights [2]. - The investigation focuses on potential securities fraud or unlawful business practices by Cepton, Inc. and its officers or directors [2]. Group 2 - The Portnoy Law Firm has a history of representing investors in claims related to corporate wrongdoing, having recovered over $5.5 billion for aggrieved investors [3].